Related references
Note: Only part of the references are listed.Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
A. Bardia et al.
ANNALS OF ONCOLOGY (2020)
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial
K. Kalinsky et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro et al.
BREAST CANCER RESEARCH (2020)
Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
Ye-Lim Park et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
Zheng Zhong et al.
ONCOGENE (2019)
CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing
Yuchao Jiang et al.
GENOME BIOLOGY (2018)
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Marc Damelin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Aravind Subramanian et al.
CELL (2017)
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
Jeffrey P. Solzak et al.
NPJ BREAST CANCER (2017)
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Boris Shor et al.
CLINICAL CANCER RESEARCH (2016)
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Josep Maria del Campo et al.
GYNECOLOGIC ONCOLOGY (2016)
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor
Huey-En Tzeng et al.
ONCOTARGET (2015)
Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing
Milan Radovich et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Triple negative breast cancer: unmet medical needs
Sumanta Kumar Pal et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers Potential Clinical Implications
Sunil Badve et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of Disease: oncogene addiction - a rationale for molecular targeting in cancer therapy
I. Bernard Weinstein et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
Shanu Modi et al.
CLINICAL BREAST CANCER (2006)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
S Modi et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates
XW Lu et al.
NATURE (2004)
Share Paper
